Clinical Effects of the Self-administered Subcutaneous Complement Inhibitor Zilucoplan in Patients With Moderate to Severe GeneralizedMyasthenia Gravis Results of a Phase 2 Randomized, Double-Blind, Placebo-Controlled, Multicenter Clinical Trial

James F. Howard Jr, Richard J. Nowak, Gil I.Wolfe, Miriam L. Freimer, Tuan H. Vu,  John L. Hinton, Michael Benatar, PetraW. Duda, James E. MacDougall, Ramin Farzaneh-Far, Henry J. Kaminski, and the Zilucoplan MG Study Group

Selezionato dal Lettore: Stefano Floro - Università Statale di Milano

Rationale of this choice is linked to the importance of finding a valuable alterntive to the most used immunosuppressive treatments for Myasthenia Gravis. An important evidence is that chronic use of steroid (and other similar drugs) have lots of side effects that influence patients’ quality of life. This trial demonstrated a substantial efficacy of Zilucoplan under clinical point of view, and analyzed accurately the safety profile and tolerability.